Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use treatment reaching a market ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

A poll conducted in April and May of 2024 found that around 12 percent of Americans have tried a GLP-1 drug such as Ozempic, Wegovy, Zepbound, or Mounjaro—a number that has likely only grown ...